CN114469808A - 一种含酵母肽的抗氧化纳米乳制备方法及在化妆品中的应用 - Google Patents
一种含酵母肽的抗氧化纳米乳制备方法及在化妆品中的应用 Download PDFInfo
- Publication number
- CN114469808A CN114469808A CN202210107491.4A CN202210107491A CN114469808A CN 114469808 A CN114469808 A CN 114469808A CN 202210107491 A CN202210107491 A CN 202210107491A CN 114469808 A CN114469808 A CN 114469808A
- Authority
- CN
- China
- Prior art keywords
- nanoemulsion
- emulsion
- weight
- antioxidant
- accounting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 59
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 54
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 title claims description 36
- 239000003963 antioxidant agent Substances 0.000 title claims description 30
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 26
- 201000004384 Alopecia Diseases 0.000 claims abstract description 19
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 18
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 18
- 239000002738 chelating agent Substances 0.000 claims abstract description 14
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 14
- 229940074391 gallic acid Drugs 0.000 claims abstract description 13
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 13
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 49
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000413 hydrolysate Substances 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 21
- 239000000839 emulsion Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 108010058643 Fungal Proteins Proteins 0.000 claims description 13
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- 231100000360 alopecia Toxicity 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 6
- 229960004025 sodium salicylate Drugs 0.000 claims description 6
- 150000005846 sugar alcohols Polymers 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 229920001992 poloxamer 407 Polymers 0.000 claims description 3
- 229940044476 poloxamer 407 Drugs 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 230000003656 anti-hair-loss Effects 0.000 abstract description 44
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract description 11
- 235000013399 edible fruits Nutrition 0.000 abstract description 9
- 240000006079 Schisandra chinensis Species 0.000 abstract description 8
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract description 8
- 230000003676 hair loss Effects 0.000 abstract description 8
- 208000024963 hair loss Diseases 0.000 abstract description 8
- 239000000047 product Substances 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000011506 response to oxidative stress Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 21
- 239000000523 sample Substances 0.000 description 18
- 239000002453 shampoo Substances 0.000 description 18
- 210000004209 hair Anatomy 0.000 description 14
- 239000012071 phase Substances 0.000 description 12
- 210000003780 hair follicle Anatomy 0.000 description 11
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 210000004761 scalp Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000002265 prevention Effects 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 230000003658 preventing hair loss Effects 0.000 description 8
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 229960000502 poloxamer Drugs 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- VFKZECOCJCGZQK-UHFFFAOYSA-M 3-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCO VFKZECOCJCGZQK-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940073499 decyl glucoside Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
本发明属日化领域,涉及一种包含酵母肽水解产物的纳米乳液及该纳米乳液制备方法及在防脱发化妆品中的应用。本发明纳米乳液包含酵母肽水解物、麦角硫因、螯合剂、乳化剂、丙二醇辛酸酯、五味子果提取物、棓酸等组分。本发明作为活性物载体,其在防脱发化妆品中的应用具有比市售产品更优异的防脱性能,解决因长期氧化应激反应导致的脱发现象的发生。
Description
技术领域
本发明属日化领域,具体涉及一种包含酵母肽水解产物的纳米乳液,本发明还涉及纳米乳液该制备方法及在防脱发化妆品中的应用。
背景技术
脱发有两种:一种是遗传因素,也就是人们常说的雄激素性脱发,这种突发类型男女都有存在,主要原因为体内的雄激素水平过于旺盛或头皮的性激素受体比较敏感.雄激素性脱发的机理为,雄激素在5-a还原酶的作用下变成二氢睾酮(DHT),DHT会导致皮肤出油长痘痘,也会让头发毛囊萎缩并抑制毛囊内的生长因子,久而久之,头发的生长就变慢,脱发现象在所难免。雄激素性脱发治疗难度大,一般是偏药物治疗并辅助一些其它产品。
除了遗传因素,人在压力大,作息不规律的情况下很容易产生脱发现象,尤其是90后和95后占到多数,这往往是由于压力的产生会影响内分泌,从而导致体内自由基增加,再加上头皮油脂氧化导致的炎症等问题,使头皮毛囊细胞的健康程度下降,无法抵御外界的侵害.此外,睡眠不足容易引发神经过度紧张,血液运行受到影响,毛囊供血不足,摄取的营养也会大大降低,从而导致所谓的年轻一族的脱发现象(见文献”Oxidative stress andalopecia areata”journal of medicine and life,[J],2015,8(Spec Issue):43.)。
一项由日本学者做过的实验,将老鼠的毛剃光,然后涂上一层油脂的过氧化物来模拟头皮油脂氧化后的产物,接着观察老鼠毛发的生长情况发现,涂抹了氧化以后的油脂后,老鼠的毛发确实变少了(见文献”The role of oxidative damage of poor scalphealth:ramifications to causality and associated hair growth”Internationaljournal of cosmetic science,2015,37:9-15.)。
另外,有公司防脱产品采用与美国FDA批准的生发剂药物-米诺地尔
(minoxidil)近似结构的二氨基嘧啶氧化物,虽然二氨基嘧啶氧化物具有近似米诺地尔的结构,具有抑制5-a还原酶的作用,但其防脱发机制尚不明确,且米诺地尔作为生发剂药物存在许多副作用。因此,有必要研究其它来自天然的产物且更加安全,具有清除自由基和抗氧化作用的活性成分及组合物,起到清除自由基、抗氧化修护头皮和毛囊的作用,实现固发防脱发的目的。
发明内容
本发明的目的之一就是研究一种纳米乳载体组合物,具体为一种具有抗氧化,抗自由基功效的纳米乳液及制备方法。另一个目的,一种含抗氧化组合物的纳米乳液应用于防脱发化妆品,促进头皮和毛囊的健康,稳固毛囊,减少毛发因过早进入衰老而脱落,解决年轻一族脱发烦恼。
一种含酵母肽的抗氧化纳米乳,其特征在于,包含一种酵母肽水解产物,麦角硫因和五味子(SCHIZANDR。A CHINENSIS)果提取物等具有抗氧化,抗自由基组合物的纳米乳,具体由以下组分组成:
(1)含有重量百分比5-12%的酵母肽水解物,所述酵母肽水解物为酿酒酵母肽水解物,所述酿酒酵母肽水解物含有0.5%水解酵母蛋白;
(2)含有重量百分比0.02-0.2%的麦角硫因;
(3)含有重量百分比0.1-0.5%螯合剂,所述螯合剂为柠檬酸和柠檬酸钠,且柠檬酸与柠檬酸钠的重量比为1;2-2:1;
(4)含有重量百分比4-11%的乳化剂,该乳化剂为含占纳米乳重量百分比1-5%的泊洛沙姆407,含占纳米乳重量百分比1-2%的泊洛沙姆188以及含占纳米乳重量百分比2-4%的氢化卵磷脂混合;
(5)含有重量百分比3%的丙二醇辛酸酯,
(6)含有重量百分比0.05-3%的五味子(SCHIZANDRA CHINENSIS)果提取物,
(7)含有重量比0.4%的棓酸,
(8)含有重量百分比0.5%的水杨酸钠,
(9)含有重量百分比10-20%的多元醇,所述多元醇为丙二醇,甘油和乙醇中任意一种,
(10)余量的水。
本发明含酵母肽的抗氧化纳米乳制作方法为:(a)油相:将丙二醇辛酸酯,五味子(SCHIZANDRA CHINENSIS)果提取物和棓酸混合在一起并搅拌溶解均匀,(b)水相:将多元醇(丙二醇,甘油或乙醇),螯合剂和乳化剂加入到去离子水中,溶解均匀备用,(c)将油相加入水相,搅拌均匀后形成预乳液,(d)预乳液中加入酵母肽水解物和麦角硫因,然后将预乳液加入到超声微反应器中进行超声乳化,其中微反应器管径1-3mm,材质为石英玻璃,温度调整至35-45℃,最终的乳液呈现半透明状态,测试粒径为100±50纳米,密度0.8900-0.9860,纳米乳粒径分布指数PDI<0.1(e)最后出料。
本发明所述含酵母肽的抗氧化纳米乳在防脱发化妆品中的应用。
本发明的有益效果
本发明有益效果(1)根据自由基清除和皮肤抗衰老机制,甄选了具有协同增效的多种抗氧化活性物作为自由基清除剂,(2)由多种抗氧化活性组合物制备的纳米乳,粒径100±50纳米,密度0.8900-0.9860,且纳米乳粒径分布均一,粒径分布指数PDI<0.1,(3)一种含酵母肽的抗氧化纳米乳,作为活性物载体,其在防脱发化妆品中的应用具有比市售产品更优异的防脱性能,解决因长期氧化应激反应导致的脱发现象的发生。
附图说明
图1纳米乳粒径分布图谱。
具体实施方式
下面结合实施例对本发明作进一步详述。
一种含酵母肽的抗氧化纳米乳,其特征在于,包含酵母肽水解产物,麦角硫因和五味子(SCHIZANDRA CHINENSIS)果提取物等抗氧化、抗自由基活性物,具体由以下组分组成:
(1)含有重量百分比5-12%的酵母肽水解物;所述酵母肽水解物为酿酒酵母肽水解物,所述酿酒酵母肽水解物含有0.5%水解酵母蛋白;
(2)含有重量百分比0.02-0.2%的麦角硫因;
(3)含有重量百分比0.1-0.5%螯合剂,所述螯合剂为柠檬酸和柠檬酸钠,且柠檬酸与柠檬酸钠的重量比为1;2-2:1;
(4)含有重量百分比4-11%的乳化剂,所述乳化剂为泊洛沙姆407 1-5%,泊洛沙姆188 1-2%,氢化卵磷脂2-4%;
(5)含有重量百分比3%的丙二醇辛酸酯;
(6)含有重量百分比0.05-3%的五味子(SCHIZANDRA CHINENSIS)果提取物;
(7)含有重量百分比0.4%的棓酸;
(8)含有重量百分比0.5%的水杨酸钠;
(9)含有重量百分比10-20%的多元醇,所述多元醇为丙二醇,甘油和乙醇中的任意一种;
(10)余量的水。
其中,所述酵母肽水解物是由69.5%的水,30%的甘油,0.5%的水解酵母蛋白,0.3%的苯甲酸钠以及0.15%的山梨酸钾组成,其中所述水解酵母蛋白为纯度100%干粉状物质;所述水解酵母蛋白是来自酿酒酵母物种的酵母蛋白的水解产物,含有0.5-5.5g/l的肽化合物。
其中,所述麦角硫因是由微生物发酵获得,活性物含量为100%,具有较好的抗氧化活性,生产厂商:中科欣杨。
其中,所述五味子(SCHIZANDRA CHINENSIS)果提取物采用超临界提取方法提取,具有较好的抗氧化活性,生产厂商:巴斯夫。
其中,所述棓酸具有较好的抗氧化活性,化学试剂级别。
其中,上述泊洛沙姆407为环氧丙烷和丙二醇反应形成聚氧丙烯乙二醇,然后乙氧基化形成的嵌段共聚物,本发明纳米乳中起到活性物增溶和乳化的功能,生产厂商:巴斯夫,
其中,泊洛沙姆188为聚氧乙烯/聚氧丙烯共聚物,属于非离子型高分子表面活性剂,通过形成胶束增加难溶活性物的溶解度,在本发明纳米乳中起到增溶和助乳化的作用。
其中,氢化卵磷脂为日本NIKKOL公司生产,在本发明纳米乳中为水包油乳化剂。
根据自由基清除和皮肤抗衰老机制,本发明甄选了不同抗氧化活性的活性物如,酵母肽水解物,麦角硫因,五味子果提取物和棓酸等四种活性物,并梯度测试所述活性物的抗氧化活性以及协同抗氧化效果(DPPH自由基清除率)见表1。
表1
*所述酵母肽来自于酿酒酵母物种酵母蛋白的水解产物,含活性多肽和十六种氨基酸,具有抗自由基功能,有助于稳固毛囊组织,酵母肽水解物的组成:水69.05%,甘油30%,水解酵母蛋白0.5%,苯甲酸钠0.3,山梨酸钾0.15%。
**所述五味子提取物。采用二氧化碳超临界萃取法提取五味子果油溶提取物,为黄色至橙色油状液体,具有特征气味,五味子总量(5-10%),抗氧化,抗衰老功能,对头发新陈代谢促进及能量增加的效应,通过刺激胶原蛋白-17和粘连蛋白-1的合成,加强真皮表皮连接的体外稳定性,增强肌肤回弹,弹性和紧致性,促进毛囊的稳固和活性。
所述麦角硫因来自于微生物合成技术获得,为白色晶体,100%活性,分子量229.3,0.02-0.2%添加量。麦角硫因是一种稀有的天然氨基酸,是体内天然存在的抗氧化剂,对细胞起到保护作用,修护毛囊,促进毛囊活力,从而有利于毛囊的稳固,防脱发。
所述培酸,又名没食子酸,具有酚和羧酸的性质,由于其特殊的结构,具有较强的抗氧化,抗突变和抗自由基的功效,能改善内皮依赖性松弛,收缩毛孔,有助于防止掉发。
简述水解酵母蛋白(酵母肽水解物)制作工艺
利用酿酒酵母资源,通过破壁预处理与复合酶降解相结合的工艺,制取特定相对分子量范围的蛋白水解物。温度55-60℃,pH值6.6-6.8,酶解时间6-7h,蛋白质提取率40-50%,经HPLC测定水解产物中,65%组分的相对分子量介于200-1000之间,最后真空冷冻成为水解酵母蛋白的干粉(干提物)。最后HPLC测试,含有蛋白质和肽化合物的水解物约占干提物总重量的30%至70%。
实施例
本发明实施例公开了一种含酵母肽的抗氧化纳米乳,制备方法及在制备防脱发化妆品中的应用。
本发明所描述的一种含酵母肽的抗氧化纳米乳可以应用添加在防脱精华液,防脱润发乳,防脱洗发水等不同剂型产品中,本发明实施例仅以防脱精华液和防脱洗发水的添加作为参考,而不是全部的实施例。基于本发明中的实施例,
本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例都属于本发明保护的范围。
实施例1
防脱发精华液(表2)
*含酵母肽的抗氧化纳米乳百分比组成:含有重量百分比10%的酵母肽水解物;所述酵母肽水解物为酿酒酵母肽水解物,所述酿酒酵母肽水解物含有0.5%水解酵母蛋白;含有重量百分比0.2%的麦角硫因;含有重量百分比0.4%螯合剂,所述螯合剂为柠檬酸和柠檬酸钠,且柠檬酸与柠檬酸钠的重量比为1:1;含有重量百分比4.5%的乳化剂,所述乳化剂为泊洛沙姆407 1%,泊洛沙姆188 1%,氢化卵磷脂2.5%;含有重量百分比3%的丙二醇辛酸酯;含有重量百分比1.5%的五味子(SCHIZANDRA CHINENSIS)果提取物;含有重量百分比0.4%的棓酸;含有重量百分比0.5%的水杨酸钠;含有重量百分比20%的甘油;余量的水。
含酵母肽的抗氧化纳米乳制作方法为:
(a)油相:将6%的丙二醇辛酸酯,1.5%五味子(SCHIZANDRA CHINENSIS)果提取物和0.4%棓酸混合在一起并搅拌溶解均匀,
(b)水相:将20%的甘油,0.4%的螯合剂和4.5%乳化剂加入到去离子水中,边搅拌边加热到45℃,溶解均匀备用,
(c)将油相加入水相,搅拌均匀后形成预乳液,
(d)将10%酵母肽水解物和0.2%麦角硫因分别加入预乳液中,搅拌均匀,之后将预乳液加入超声微反应器中进行超声乳化,其中超声微反应器管径1-3mm,材质为石英玻璃,温度调整至35-38℃,最终的乳液呈现透明状态,测试粒径为100±50纳米,密度0.8900-0.9860,PDI=0.041(见图1,粒径分别指数PDI通常<0.1代表乳液的粒径均一,PDI越小代表粒径分布的曲线越窄。PDI越小证明乳液做的越均一,各项性能也更优异,本发明纳米乳粒径指数PDI=0.041代表含酵母肽的抗氧化纳米乳的粒径分布非常均匀,因此性能(比如吸收性和稳定性)更加优异。
(e)最后出料。
实施例1本发明防脱发精华液制作方法:
(1)将0.1%的EDTA二钠,5%的甘油,1%的泛醇,0.5的水杨酸钠,1%人参根提取物,1%侧柏叶提取物分别加入水中,搅拌溶解;
(2)将香精适量加入2%PEG-40氢化蓖麻油,搅拌溶解后加入(1)中搅拌;
(3)最后分别将10%纳米乳和25%的乙醇分别加入(1)中搅拌直到体系透明。
实施例2
防脱发精华液(空白对照样)(表3)
实施例2防脱精华液-空白对照样制造方法同实施例1
实施例3(市售对照样品--某L防脱精华液样品)
L防脱精华液中含有二氨基嘧啶氧化物)
实施例4
防脱发洗发水(表4)
其中,*含酵母肽的抗氧化纳米乳的百分比组成为:10%的酵母肽水解物(酵母肽水解物的组成:水69.05%,甘油30%,水解酵母蛋白0.5%,苯甲酸钠0.3,山梨酸钾0.15%);0.2%的麦角硫因,0.4%的螯合剂(柠檬酸和柠檬酸钠的重量比为1:1),4.5%的乳化剂(其中泊洛沙姆407 1%,泊洛沙姆188 1%,氢化卵磷脂2.5%,3%的丙二醇辛酸酯,0.4%的棓酸,0.5%的水杨酸钠,20%的甘油,余量的水。
含酵母肽的抗氧化纳米乳制作方法:(a)油相:将丙二醇辛酸酯,五味子(SCHIZANDRA CHINENSIS)果提取物和棓酸混合在一起并搅拌溶解均匀,(b)水相:将多元醇,螯合剂和乳化剂加入到去离子水中,溶解均匀备用,(c)将油相加入水相,搅拌均匀后形成预乳液,(d)将酵母肽水解物和麦角硫因分别加入预乳液中,搅拌均匀,之后将预乳液加入到超声微反应器中,其中超声微反应器管径1-3mm,材质为石英玻璃,温度调整至35-38℃,最终的乳液呈现透明状态,测试粒径为100±50纳米,密度0.8900-0.9860,纳米乳粒径分布指数PDI=0.048(e)最后出料。
防脱发洗发水制备方法:
加入适量柠檬酸到足量去离子水里,加热溶解后加入3g瓜儿胶羟丙基三甲基氯化铵,搅拌溶解后分别加入160.0g月桂醇聚醚硫酸钠、40.0g椰油酰胺丙基甜菜碱、30.0g癸基葡糖苷,搅拌溶解后加入40.0g丙烯酸(酯)类共聚物,分散均匀。降温到45℃分别加入5g人参根提取物和5g侧柏叶提取物,以及适量的防腐剂,香精和食盐。降温到39℃加入80g纳米乳,搅拌均匀后出料。实施例5(防脱洗发水空白对照样品)
防脱发洗发水(空白对照样)(表5)
实施例5防脱发洗发水(空白对照样)制备方法
加入适量柠檬酸到足量去离子水里,加热溶解后加入3g瓜儿胶羟丙基三甲基氯化铵,搅拌溶解后分别加入160.0g月桂醇聚醚硫酸钠、40.0g椰油酰胺丙基甜菜碱、30.0g癸基葡糖苷,搅拌溶解后加入40.0g丙烯酸(酯)类共聚物,分散均匀。降温到45℃再分别加入适量的防腐剂,香精和食盐。搅拌均匀后出料。
实施例6(防脱洗发水-某市售对照样品)
防脱发洗发水(市售对照样)
市售对照样中含有二氨基嘧啶氧化物
功效验证
本发明一种含酵母肽的抗氧化纳米乳及在防脱化妆品中的应用.
本发明一种含酵母肽的抗氧化纳米乳可以应用在防脱精华液,防脱润发乳,防脱洗发水等不同剂型产品中,本发明以防脱精华液和防脱洗发水为例,其功效验证方式如下:
将本发明实施例1制得的防脱精华液分别与实施例2(防脱精华液-空白)和实施例3(市售防脱精华液)进行对比;
将本发明实施例4制得的防脱洗发水分别与实施例5(防脱洗发水-空白对照)和实施例6(防脱洗发水-市售样品)进行对比,实验过程及结果如下:
1.样品
实施例1制得的防脱精华液-本发明,实施例4制得的防脱洗发水-本发明,
实施例2(防脱精华液-空白)、实施例3(防脱精华液-某市售样品)、
实施例5(防脱洗发水-本发明)以及实施例6(防脱洗发水-某市售样品)
2.实验方法
选取自愿者300人(男性150人,女性150人,年龄18-35岁),曾经常熬夜,工作压力较大等基本情况,经常或偶发性头发掉落偏多现象;发质方面,头发偏油;无化妆品过敏史。
将志愿者分成6组,每组50人,男女比例各半。
第一组,试用实施例1(防脱精华液-本发明);第二组,试用实施例2(防脱精华液-空白对照);第三组,试用实施例3(防脱精华液-市售样品);
第四组,试用实施例4(防脱洗发水-本发明);第五组,试用实施例5(防脱洗发水-空白对照);第六组,使用实施例6(防脱洗发水-市售样品)。
使用方法:防脱精华液:取大约3-5毫升精华液均匀涂抹于清洁后的头皮和头发上,轻轻按摩头皮3-5分钟,不需冲洗。
使用方法:防脱洗发水:取大约4-6毫升洗发水,均匀涂抹于用水打湿后的头皮和头发上,轻轻按摩头皮3-5分钟,用水冲洗。
试用者产品防脱发功效评价方法:
试验结果(见表6)
试用者产品调查评审表6
有效率统计“明显改善”和“缓解”两个数据,然后计算有效率。
表中的结果显示:本发明防脱精华液(第一组,实施例1)和本发明防脱洗发水(第四组,实施例4)的有效率明显高于空白对照和市售样品的有效率。
此外,为了进一步验证本发明一种含酵母肽的抗氧化纳米乳及在防脱化妆品中的应用具备的功效,分别测试实施例1-6,六个样品的5-a还原酶的抑制效果,从而佐证其控油防脱的效果。
详细介绍如下:
睾酮(T)在5α-还原酶的作用下转化为活性更强的双氢睾酮(DHT),DHT对毛囊敏感,影响毛囊发育,容易引发脂溢性脱发。通过分析受试物是否能够抑制5α-还原酶,从而抑制DHT的生成,可以作为判断是否具有防脱育发功效的依据之一。
实验材料
Ⅱ型5α-还原酶:提取自大鼠前列腺组织,保存于-80℃
阳性对照(PC):非那雄胺0.4μM
样品制备(TA):用磷酸盐缓冲液(PBS)稀释样品,测试浓度为100%,50%,30%,10%
空白对照:磷酸盐缓冲液(PBS)
实验步骤
Ⅱ型5α-还原酶的制备:取雄性大鼠10只,禁食不禁水过夜后脱颈椎处死,取出前列腺于冰台上剪碎。于0℃下用预冷的缓冲液在玻璃匀浆器制成1:5匀浆,3000g离心10min,取上清液10000g离心45min,取上清分装至EP管中,每管1mL,即为酶提取物,-80℃冰箱保存。
Ⅱ型5α-还原酶活性测定:在2mL反应体系中含有:磷酸盐缓冲液0.25mL,酶提取物0.70mL,睾酮溶液(0.5mg/mL)0.1mL,NADPH溶液(1mg/mL)0.35mL,10%乙醇(阳性对照管中为0.4μM非那雄胺,样品管中为样品溶液)0.6mL。对照管将酶提取物替换为磷酸缓冲液,并加入2.0mL二氯甲烷终止反应;样品管在37℃下反应30min,反应结束后加入2.0mL二氯甲烷使反应停止,震荡1min后3000r/min离心10min。去除上层水相,移出约1.0mL有机相并蒸干,残留物溶于1.0mL甲醇,采用高效液相色谱法测定睾酮峰面积(T)。每个反应设3个平行管。
5-a还原酶抑制率计算公式(式Ⅰ):
式Ⅰ(5α-还原酶抑制率%计算公式)
实验结果(见表7)
表7:5α-还原酶抑制率(%)
*:代表具有统计学意义
实施例1(防脱精华液-本发明)测试结果:
样品在浓度为100%,50%,30%,10%时可以显著抑制Ⅱ型5α-还原酶活性,
实施例2(防脱精华液-空白)测试结果:
样品在浓度为100%时可以显著抑制Ⅱ型5α-还原酶活性,
实施例3(防脱精华液-市售)测试结果:
样品在浓度为100%,50%,30%时可以显著抑制Ⅱ型5α-还原酶活性,
实施例4(防脱洗发水-本发明)测试结果:
样品在浓度为50%,30%,10%时可以显著抑制Ⅱ型5α-还原酶活性,
实施例5(防脱洗发水-空白)测试结果:
样品在浓度为50%时可以显著抑制Ⅱ型5α-还原酶活性,
实施例6(防脱洗发水-市售)测试结果:
样品在浓度为50%,30%时可以显著抑制Ⅱ型5α-还原酶活性,
综合以上表7实验结果,本发明实施例1防脱精华液和本发明实施例4防脱洗发分别在不同测试浓度下,所测试的Ⅱ型5α-还原酶抑制率结果均高于空白样和市售样品。
Claims (3)
1.一种含酵母肽的抗氧化纳米乳,由以下组分组成:
(1)占纳米乳重量百分比5-12%的酵母肽水解物,所述酵母肽水解物为酿酒酵母肽水解物,该酿酒酵母肽水解物含有0.5%水解酵母蛋白;
(2)占纳米乳重量百分比0.02-0.2%的麦角硫因;
(3)占纳米乳重量百分比0.1-0.5%螯合剂,该螯合剂为柠檬酸和柠檬酸钠,且柠檬酸与柠檬酸钠的重量比为1:2-2:1;
(4)占纳米乳重量百分比4-11%的乳化剂,该乳化剂为含占纳米乳重量百分比1-5%的泊洛沙姆407,含占纳米乳重量百分比1-2%的泊洛沙姆188以及含占纳米乳重量百分比2-4%的氢化卵磷脂混合;
(5)占纳米乳重量百分比3%的丙二醇辛酸酯;
(6)占纳米乳重量百分比0.05-3%的五味子果提取物;
(7)占纳米乳重量百分比0.4%的棓酸;
(8)占纳米乳重量百分比0.5%的水杨酸钠;
(9)占纳米乳重量百分比10-20%的多元醇,该多元醇为丙二醇,甘油和乙醇中任意一种;
(10)余量的水。
2.根据权利要求1所述的抗氧化纳米乳,其制作方法为:
(a)油相:将丙二醇辛酸酯,五味子果提取物和棓酸混合在一起并搅拌溶解均匀;
(b)水相:将多元醇,螯合剂和乳化剂加入到去离子水中,溶解均匀备用;
(c)将油相加入水相,搅拌均匀后形成预乳液;
(d)预乳液中加入酵母肽水解物和麦角硫因,然后将预乳液加入到超声微反应器中,其中微反应器管径1-3mm,材质为石英玻璃,温度调整至35-45℃,最终的乳液呈现半透明状态,测试粒径为100±50纳米,密度0.8900-0.9860,粒径指数PDI<0.1(e)最后出料。
3.权利要求1所述含酵母肽的抗氧化纳米乳在防脱发化妆品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210107491.4A CN114469808B (zh) | 2022-01-28 | 2022-01-28 | 一种含酵母肽的抗氧化纳米乳制备方法及在化妆品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210107491.4A CN114469808B (zh) | 2022-01-28 | 2022-01-28 | 一种含酵母肽的抗氧化纳米乳制备方法及在化妆品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114469808A true CN114469808A (zh) | 2022-05-13 |
CN114469808B CN114469808B (zh) | 2024-03-19 |
Family
ID=81476520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210107491.4A Active CN114469808B (zh) | 2022-01-28 | 2022-01-28 | 一种含酵母肽的抗氧化纳米乳制备方法及在化妆品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114469808B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117598940A (zh) * | 2023-11-16 | 2024-02-27 | 广州中妆美业化妆品有限公司 | 一种具有抗氧化、抗皱和紫外损伤修护功效的茶嫩蛋白组合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101027071A (zh) * | 2004-08-10 | 2007-08-29 | 赫利科生株式会社 | 预防和治疗脱发症和脂溢性皮肤病的包含软枣猕猴桃提取物的组合物 |
US20130296251A1 (en) * | 2009-04-15 | 2013-11-07 | Claude Dal Farra | Cosmetic and/or pharmaceutical composition comprising a yeast peptide hydrolysate and use of the yeast peptide hydrolysate as an active agent for strengthening hair |
CN105748400A (zh) * | 2016-04-25 | 2016-07-13 | 广州市暨生元生物科技有限公司 | 一种酵母多肽冻干粉面膜组合及其制作方法 |
CN106491482A (zh) * | 2016-10-08 | 2017-03-15 | 拉芳家化股份有限公司 | 一种含抗老化及防脱复合剂的护发组合物 |
CN108836901A (zh) * | 2018-09-26 | 2018-11-20 | 嫦娥创新(武汉)生物科技有限公司 | 一种含酵母菌发酵产物滤液的面膜精华液及其制备方法 |
CN112516006A (zh) * | 2020-12-10 | 2021-03-19 | 武汉百思凯瑞生物科技有限公司 | 一种具有防脱生发、固发、黑发功能的纳米组合物及其制备方法和应用 |
-
2022
- 2022-01-28 CN CN202210107491.4A patent/CN114469808B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101027071A (zh) * | 2004-08-10 | 2007-08-29 | 赫利科生株式会社 | 预防和治疗脱发症和脂溢性皮肤病的包含软枣猕猴桃提取物的组合物 |
US20130296251A1 (en) * | 2009-04-15 | 2013-11-07 | Claude Dal Farra | Cosmetic and/or pharmaceutical composition comprising a yeast peptide hydrolysate and use of the yeast peptide hydrolysate as an active agent for strengthening hair |
CN105748400A (zh) * | 2016-04-25 | 2016-07-13 | 广州市暨生元生物科技有限公司 | 一种酵母多肽冻干粉面膜组合及其制作方法 |
CN106491482A (zh) * | 2016-10-08 | 2017-03-15 | 拉芳家化股份有限公司 | 一种含抗老化及防脱复合剂的护发组合物 |
CN108836901A (zh) * | 2018-09-26 | 2018-11-20 | 嫦娥创新(武汉)生物科技有限公司 | 一种含酵母菌发酵产物滤液的面膜精华液及其制备方法 |
CN112516006A (zh) * | 2020-12-10 | 2021-03-19 | 武汉百思凯瑞生物科技有限公司 | 一种具有防脱生发、固发、黑发功能的纳米组合物及其制备方法和应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117598940A (zh) * | 2023-11-16 | 2024-02-27 | 广州中妆美业化妆品有限公司 | 一种具有抗氧化、抗皱和紫外损伤修护功效的茶嫩蛋白组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114469808B (zh) | 2024-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106176566B (zh) | 具有美白功效的化妆品组合物及其制备方法 | |
JP4099173B2 (ja) | コンブチャ(kombucha)を含む化粧品または皮膚用薬組成物 | |
EP1755547B1 (en) | Haircare compositions and methods | |
KR101851388B1 (ko) | 진세노사이드의 경피흡수 촉진용 조성물, 이의 제조방법 및 상기 조성물을 함유하는 탈모방지 화장료 조성물 | |
KR101917774B1 (ko) | 블랙커민씨드 추출물을 유효성분으로 포함하는 화장품 보존용 조성물 | |
KR101629502B1 (ko) | 세정효과가 우수한 저자극 클렌징 워터 화장료 조성물 | |
KR101931299B1 (ko) | 소포로리피드를 유효성분으로 함유하는 탈모방지 또는 발모촉진용 조성물 | |
KR100801164B1 (ko) | 탈모방지 및 발모촉진 조성물과 그 제조방법 및 이를 이용한 헤어 화장품 조성물 | |
CN114469808A (zh) | 一种含酵母肽的抗氧化纳米乳制备方法及在化妆品中的应用 | |
CN111514058A (zh) | 一种皮肤美白提亮剂及其制备方法 | |
CN112370393B (zh) | 一种洗发慕斯组合物及其制备方法与应用 | |
CN113633573A (zh) | 一种美白淡斑精华液及其制备方法 | |
TW202106323A (zh) | 迷迭香癒傷組織萃取物用於製備抑制肌膚老化的組合物之用途以及用以誘導迷迭香癒傷組織的培養基 | |
CN114869817B (zh) | 一种具有美白功效的组合物及其制备方法 | |
CN111686023A (zh) | 一种保加利亚玫瑰晶露及其制备方法 | |
CN113633599B (zh) | 一种含铁皮石斛提取物的肌底精华液及其制备方法 | |
JP4643789B2 (ja) | 皮膚外用剤 | |
CN113749972B (zh) | 一种具有抗皱效果的组合物及其在化妆品中的应用 | |
CN111743798B (zh) | 一种多效抗衰护肤品及其制备方法 | |
CN115105425A (zh) | 一种敏感肌肤修复组合物及其应用 | |
JP4675770B2 (ja) | 紫外線によるTGF−βレセプターの産生低下改善剤 | |
TW202210061A (zh) | 山葵葉萃取物用於抑制皮膚痤瘡形成及減少痤瘡桿菌分泌物之用途 | |
KR101509241B1 (ko) | 여드름 예방 및 개선용 화장료 조성물 | |
CN116440049B (zh) | 一种适用于敏感肌和具有修复皮肤屏障功效的美白组合物及其应用 | |
TWI801738B (zh) | 苦蕎麥種皮萃取物用於降低彈力蛋白流失的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |